In the past week, TRVI stock has gone up by 8.25%, with a monthly decline of -12.61% and a quarterly surge of 6.75%. The volatility ratio for the week is 6.39%, and the volatility levels for the last 30 days are 5.69% for Trevi Therapeutics Inc The simple moving average for the last 20 days is 3.65% for TRVI’s stock, with a simple moving average of 31.46% for the last 200 days.
Is It Worth Investing in Trevi Therapeutics Inc (NASDAQ: TRVI) Right Now?
TRVI has 36-month beta value of 0.57. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRVI is 69.87M, and currently, short sellers hold a 10.92% ratio of that float. The average trading volume of TRVI on July 10, 2025 was 1.76M shares.
TRVI) stock’s latest price update
Trevi Therapeutics Inc (NASDAQ: TRVI)’s stock price has gone rise by 5.38% in comparison to its previous close of $5.86, however, the company has experienced a 8.25% increase in its stock price over the last five trading days. prnewswire.com reported 2025-07-01 that NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, and Lisa Delfini, Chief Financial Officer, will be attending Leerink Partners Therapeutics Forum: I&I and Metabolism, held from July 8-9 in Boston, Massachusetts.
Analysts’ Opinion of TRVI
Many brokerage firms have already submitted their reports for TRVI stocks, with Cantor Fitzgerald repeating the rating for TRVI by listing it as a “Overweight.” The predicted price for TRVI in the upcoming period, according to Cantor Fitzgerald is $25 based on the research report published on July 01, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see TRVI reach a price target of $21. The rating they have provided for TRVI stocks is “Buy” according to the report published on May 28th, 2025.
Raymond James gave a rating of “Strong Buy” to TRVI, setting the target price at $29 in the report published on March 10th of the current year.
TRVI Trading at -1.73% from the 50-Day Moving Average
After a stumble in the market that brought TRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.51% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRVI starting from SCIASCIA THOMAS, who sale 2,631 shares at the price of $6.60 back on Mar 25 ’25. After this action, SCIASCIA THOMAS now owns 221,373 shares of Trevi Therapeutics Inc, valued at $17,365 using the latest closing price.
GOOD JENNIFER L, the President & CEO of Trevi Therapeutics Inc, sale 5,263 shares at $6.58 during a trade that took place back on Mar 21 ’25, which means that GOOD JENNIFER L is holding 213,313 shares at $34,625 based on the most recent closing price.
Stock Fundamentals for TRVI
The total capital return value is set at -0.51. Equity return is now at value -55.12, with -51.03 for asset returns.
Based on Trevi Therapeutics Inc (TRVI), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -43.12. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -17029.67.
Currently, EBITDA for the company is -51.52 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.38.
Conclusion
To put it simply, Trevi Therapeutics Inc (TRVI) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
